Broad-spectrum therapeutics for influenza are critically needed to address the problem of influenza pandemics, a major threat to the public health globally. We have proposed studies that aim at generating a novel class of fusion proteins capable of blocking infections by all strains of influenza viruses. Specifically, the fusion protein is composed of a protease inhibitor that inhibits activation of all influenza viruses and an anchoring domain that helps to enrich the drug and prolong the drug retention on the respiratory epithelium. In the proposed phase I study, we will generate this proteinase inhibitor and its fusion proteins, compare their functional activities in vitro and choose the best construct for phase II study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43AI060188-02
Application #
6946426
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (10))
Program Officer
Lacourciere, Karen A
Project Start
2004-09-15
Project End
2007-08-31
Budget Start
2005-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2005
Total Cost
$500,000
Indirect Cost
Name
Nexbio, Inc.
Department
Type
DUNS #
140600268
City
San Diego
State
CA
Country
United States
Zip Code
92121